The purpose of this Phase II single-arm study is to prospectively explore the efficacy of chemotherapy plus EGFR inhibitors in patients with liver metastases from total wild-type colorectal cancer with ctDNA superselective negative genes.
18-75 years (including 18 and 75 years);
ECOG PS 0 or 1;
Colorectal cancer diagnosed histologically and/or cytologically with metastatic or recurrent lesions that are not curable with surgery;
Patients with liver metastases of RAS wild-type colorectal cancer who have not received prior treatment;
Pregnant or lactating women;
Patients with a known history of allergy to any investigative drug, similar drug, or excipient;
Patients with risk of massive gastrointestinal bleeding or gastrointestinal obstruction;
Patients with a history of thromboembolism, except thrombosis caused by PICC;